Statistical analysis revealed that IGF2BP2 expression was consistent with the degree of malignancy (i.e., tumor size, lymph node metastasis, and stage; Table 1). This evidence concerns the gene IGF2BP2 and metastatic malignant neoplasm in the lymph nodes.